HU914133D0 - Linking molecules being to split off by means of acids - Google Patents
Linking molecules being to split off by means of acidsInfo
- Publication number
- HU914133D0 HU914133D0 HU914133A HU413391A HU914133D0 HU 914133 D0 HU914133 D0 HU 914133D0 HU 914133 A HU914133 A HU 914133A HU 413391 A HU413391 A HU 413391A HU 914133 D0 HU914133 D0 HU 914133D0
- Authority
- HU
- Hungary
- Prior art keywords
- aralkyl
- aryl
- lower alkyl
- alkylene
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90203526 | 1990-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
HU914133D0 true HU914133D0 (en) | 1992-03-30 |
HUT60484A HUT60484A (en) | 1992-09-28 |
Family
ID=8205218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU914133A HUT60484A (en) | 1990-12-31 | 1991-12-28 | Process for applying acid-splitted connecting molecules for the controlled release of biologically active compounds |
Country Status (17)
Country | Link |
---|---|
US (1) | US5306809A (hu) |
EP (1) | EP0495265B1 (hu) |
JP (1) | JPH04334377A (hu) |
KR (1) | KR920012063A (hu) |
AT (1) | ATE109476T1 (hu) |
AU (1) | AU646121B2 (hu) |
CA (1) | CA2058595A1 (hu) |
DE (1) | DE69103255T2 (hu) |
DK (1) | DK0495265T3 (hu) |
ES (1) | ES2061166T3 (hu) |
FI (1) | FI101678B1 (hu) |
HU (1) | HUT60484A (hu) |
IE (1) | IE65406B1 (hu) |
NO (1) | NO180417C (hu) |
NZ (1) | NZ241217A (hu) |
PT (1) | PT99954B (hu) |
ZA (1) | ZA9110203B (hu) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5505931A (en) * | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
EP0638583A1 (en) * | 1993-08-13 | 1995-02-15 | Hoechst Aktiengesellschaft | Aminosugar active substances, a process for their preparation and use as pharmaceuticals |
DE4433890C2 (de) * | 1994-09-22 | 1999-02-18 | Deutsches Krebsforsch | Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein |
PT871490E (pt) * | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
US6800616B2 (en) * | 1998-02-26 | 2004-10-05 | Supergen, Inc. | Treatment of HIV infections |
CA2248592A1 (en) | 1998-08-31 | 2000-02-29 | Christopher D. Batich | Microspheres for use in the treatment of cancer |
US6140015A (en) * | 1998-12-10 | 2000-10-31 | International Business Machines Corporation | Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching |
TWI242000B (en) * | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
CA2358420C (en) * | 1999-03-11 | 2010-03-16 | Ardenia Investments Ltd. | New compounds for the treatment of cancer |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
BRPI0003386B8 (pt) * | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas |
HUP0303719A2 (hu) * | 2000-10-16 | 2004-03-01 | Neopharm, Inc. | Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra |
EP2335728A1 (en) | 2001-05-11 | 2011-06-22 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
GB0116143D0 (en) * | 2001-07-02 | 2001-08-22 | Amersham Pharm Biotech Uk Ltd | Chemical capture reagent |
KR100507968B1 (ko) * | 2001-08-18 | 2005-08-17 | 한국과학기술연구원 | 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법 |
EP1501352B1 (en) * | 2001-12-14 | 2015-02-18 | The University Of Wyoming | Controlled release of oxycodone |
US8361464B2 (en) | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
AU2003220091B2 (en) * | 2002-03-08 | 2006-02-16 | Emory University | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
US20050069551A1 (en) * | 2002-03-08 | 2005-03-31 | Emory University | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis |
JP2005529931A (ja) * | 2002-05-24 | 2005-10-06 | マイラス コーポレイション | 膜相互作用の可逆的改質 |
CN1733314A (zh) * | 2004-08-11 | 2006-02-15 | 张阳德 | 半乳糖化白蛋白磁性阿霉素纳米粒的制备方法 |
WO2006052900A2 (en) | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
EP2311880A3 (en) | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
KR20090091145A (ko) | 2006-10-27 | 2009-08-26 | 웨이-치앙 션 | 지질화된 인터페론 및 이의 용도 |
CN104043123B (zh) * | 2007-01-25 | 2019-08-13 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
CN101688229B (zh) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
CN101896503B (zh) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
WO2010011684A2 (en) * | 2008-07-21 | 2010-01-28 | The Regents Of The University Of California | Prodrug and fluoregenic compositions and methods for using the same |
US9051354B2 (en) | 2009-03-17 | 2015-06-09 | The University Of Tokyo | Protein charge regulator and protein-encapsulating polymer micelle complex |
WO2010111664A1 (en) * | 2009-03-26 | 2010-09-30 | Institute For Systems Biology | Improved method to determine protein interaction sites |
AU2010268690B2 (en) | 2009-07-03 | 2011-11-10 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US9315581B2 (en) | 2009-12-23 | 2016-04-19 | A Vipep Pty Limited | Immuno-conjugates and methods for producing them |
CN103080125A (zh) | 2010-07-02 | 2013-05-01 | 安吉奥开米公司 | 用于治疗性结合物的短且含d氨基酸的多肽及其使用 |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
DK2744931T3 (en) | 2011-08-18 | 2018-08-06 | Affinity Biosciences Pty Ltd | SOLUBLE POLYPEPTIDES |
PT2802606T (pt) | 2012-01-10 | 2018-07-13 | Biogen Ma Inc | Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
WO2014057436A2 (en) | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Anticancer conjugate |
WO2014124227A1 (en) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
EP3104857A4 (en) | 2014-02-14 | 2017-10-11 | The Regents of The University of California | Cyclic peroxides as prodrugs for selective delivery of agents |
CA2963218C (en) | 2014-10-03 | 2023-10-24 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
EA034582B1 (ru) | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
DK3331902T3 (da) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | Konstruktioner med et sirp-alpha-domæne eller en variant deraf |
JP6810146B2 (ja) | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス.ウ.セ. | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
WO2018118015A1 (en) | 2016-12-19 | 2018-06-28 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
US10800817B2 (en) | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
US11180534B1 (en) | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
US20230277682A1 (en) * | 2022-01-14 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631190A (en) * | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4744981A (en) * | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
US5140013A (en) * | 1989-11-28 | 1992-08-18 | Universite Laval | Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers |
-
1991
- 1991-12-27 FI FI916131A patent/FI101678B1/fi active
- 1991-12-27 JP JP3361486A patent/JPH04334377A/ja active Pending
- 1991-12-28 HU HU914133A patent/HUT60484A/hu unknown
- 1991-12-30 DK DK91203439.4T patent/DK0495265T3/da active
- 1991-12-30 CA CA002058595A patent/CA2058595A1/en not_active Abandoned
- 1991-12-30 DE DE69103255T patent/DE69103255T2/de not_active Expired - Fee Related
- 1991-12-30 PT PT99954A patent/PT99954B/pt not_active IP Right Cessation
- 1991-12-30 AU AU90098/91A patent/AU646121B2/en not_active Ceased
- 1991-12-30 ES ES91203439T patent/ES2061166T3/es not_active Expired - Lifetime
- 1991-12-30 ZA ZA9110203A patent/ZA9110203B/xx unknown
- 1991-12-30 AT AT91203439T patent/ATE109476T1/de active
- 1991-12-30 EP EP91203439A patent/EP0495265B1/en not_active Expired - Lifetime
- 1991-12-30 IE IE456791A patent/IE65406B1/en not_active IP Right Cessation
- 1991-12-30 KR KR1019910025982A patent/KR920012063A/ko not_active Application Discontinuation
- 1991-12-31 US US07/815,671 patent/US5306809A/en not_active Expired - Fee Related
-
1992
- 1992-01-02 NO NO920040A patent/NO180417C/no unknown
- 1992-01-06 NZ NZ241217A patent/NZ241217A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0495265B1 (en) | 1994-08-03 |
PT99954A (pt) | 1993-06-30 |
FI916131A (fi) | 1992-07-01 |
DE69103255D1 (de) | 1994-09-08 |
FI916131A0 (fi) | 1991-12-27 |
AU9009891A (en) | 1993-01-28 |
JPH04334377A (ja) | 1992-11-20 |
NO920040L (no) | 1992-07-01 |
FI101678B (fi) | 1998-08-14 |
US5306809A (en) | 1994-04-26 |
NO920040D0 (no) | 1992-01-02 |
PT99954B (pt) | 1999-06-30 |
FI101678B1 (fi) | 1998-08-14 |
ATE109476T1 (de) | 1994-08-15 |
HUT60484A (en) | 1992-09-28 |
NO180417B (no) | 1997-01-06 |
NO180417C (no) | 1997-04-16 |
AU646121B2 (en) | 1994-02-10 |
ZA9110203B (en) | 1993-01-27 |
KR920012063A (ko) | 1992-07-25 |
EP0495265A1 (en) | 1992-07-22 |
IE65406B1 (en) | 1995-10-18 |
ES2061166T3 (es) | 1994-12-01 |
IE914567A1 (en) | 1992-07-01 |
CA2058595A1 (en) | 1992-07-01 |
DK0495265T3 (da) | 1995-01-02 |
NZ241217A (en) | 1993-12-23 |
DE69103255T2 (de) | 1994-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU914133D0 (en) | Linking molecules being to split off by means of acids | |
ATE294592T1 (de) | Thioether enthaltende konjugate | |
FI912285A0 (fi) | Nya bifunktionella kopplingsfoereningar, konjugat och foerfaranden foer framstaellning av dessa. | |
MXPA03010432A (es) | Inmunoconjugados del anticuerpo cd44 citotoxico. | |
PH18031A (en) | Immunoglobulin conjugates,process for preparing them and pharmaceutical composition containing the same | |
NO178186C (no) | Forbindelser som kan koble metallioner til biologisk nyttige molekyler | |
FI915780A (fi) | Maerktae, modifierade oligonukleotider. | |
FI102077B1 (fi) | Magneettisia proteiinikonjugaatteja, menetelmä niiden valmistamiseksi ja niiden käyttö | |
WO2004041307A3 (en) | Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy | |
WO1996040664A3 (en) | Preparation of immunogens and other conjugates of drugs | |
AU6997094A (en) | Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFC4 | Cancellation of temporary protection due to refusal |